Navigation Links
Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
Date:12/6/2012

uing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, our ability to secure new partnerships and collaborations, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2011, our Form 10-Q for the quarter ended September 30, 2012, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

(Logo: http://photos.prnewswire.com/prnh/20120131/LA44118LOGO)

CONTACTS:
Investors: Bernie Hertel,
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
2. Inovio Pharmaceuticals to Present at Noble Financial Life Sciences Conference
3. Inovios Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science
4. Inovio Pharmaceuticals to Present at Noble Financial 8th Annual Equity Conference
5. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
6. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
7. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
8. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
10. Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference
11. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2014)... 2014 Dr. Carl Peck, ... today that Janet B. Arrowsmith, MD, has joined ... Partners Premier Experts are top tier consultants whose ... extraordinary value to the company’s clients. Premier Experts ... help clients successfully develop their medical products, pursue ...
(Date:8/22/2014)... Dallas, Texas (PRWEB) August 23, 2014 ... on the current state of the Papain industry ... basic overview of the industry, including definitions, applications ... Chinese domestic market analysis are provided with a ... of the market. A comparison between the international ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Today the Academy ... the United States Court of Appeals for the D.C. Circuit ... Aircraft published in the Federal Register on June 25, 2014. ... is contrary to the text and intent of the FAA ... violates Congress’ specific prohibition on any new rules or regulations ...
(Date:8/22/2014)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced results ... Biorem,s complete 2014 second quarter financial statements and MD&A have been filed ... June 30, , Six-months ended June 30, ( in CDN$,000 ... , 2014 , 2013 Revenue , 2,459 ... Gross profit , 56 , 1,485 , ...
Breaking Biology Technology:Noted Epidemiologist and Former FDA Deputy Director Janet B. Arrowsmith, MD, Joins NDA Partners as a Premier Expert Consultant 2Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 2Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 3AMA Files Petition for Review of FAA’s Interpretive Rule 2Biorem Reports 2014 Second Quarter Results 2Biorem Reports 2014 Second Quarter Results 3
... IgG1 Using UNOsphere S and CHT , ... , Henry Lai, PhD, and Samuel G Franklin, PhD, ... USA , , ... a variety of sources have been purified , using ...
... Agencourt offers primer walking sequencing of PCR products, ... submit your template in either raw or , ... Select from either single stranded coverage for confirmation sequencing , ... clone validation , purposes. , ...
... , RNAClean is a ... isolates RNA or cDNA from in vitro transcription, cDNA or RNA ... As gene expression profiling , analysis and ... effective, automated purification reagent is required. Traditional purification , ...
Cached Biology Technology:Purification of Murine IgG1 Using UNOsphere S and CHT , Ceramic Hydroxyapatite Chromatography, Rev A 2Purification of Murine IgG1 Using UNOsphere S and CHT , Ceramic Hydroxyapatite Chromatography, Rev A 3Purification of Murine IgG1 Using UNOsphere S and CHT , Ceramic Hydroxyapatite Chromatography, Rev A 4Primer Walking 2RNA & cDNA Purification Using RNAClean 2RNA & cDNA Purification Using RNAClean 3RNA & cDNA Purification Using RNAClean 4RNA & cDNA Purification Using RNAClean 5
(Date:8/22/2014)... DUBLIN , August 22, 2014 ... Markets ( http://www.researchandmarkets.com/research/mtm27l/biometrics_market ) has announced the ... North America 2014-2018"  report to their ... , , ,Biometrics is a technology ... individuals based on their physical or ...
(Date:8/22/2014)... Thomson Reuters , a leading source of information for ... University of California, Riverside in its 2014 list of ... times." , To generate the list, the company analyzed ... whose published work has had enormous impact. , The ... individuals who published the greatest number of highly cited ...
(Date:8/22/2014)... CA Research presented at the 29th Annual ... developed by Hera Therapeutics Inc. combats three types ... 70 percent of all cervical cancer. , When ... blocked the replication of HPV-16, HPV-18 and HPV-11 ... Thomas Broker, Ph.D., who presented the findings at ...
Breaking Biology News(10 mins):Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 2Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 35 UC Riverside scientists among world's most influential scientific minds 2
... infants should focus not only on what babies are being ... to a study to be presented Saturday, April 28, at ... Adding cereal to bottles is one unhealthy practice that is ... lead to overfeeding and excess weight gain in infants. ...
... change can greatly impact biological species and ecosystems, ... to accommodate habitat shifts. Recorded data already ... to regions where their climatic requirements are better ... and regulators on climate change implications for local ...
... beauty as a tourist draw can boost conservation in ... ticket out of poverty for the humans who live ... who benefit most from nature-based tourism are people who ... time breaking into the tourism business, according to the ...
Cached Biology News:Low-income moms under stress may overfeed infants 2Workshop to focus on conservation management and climate change 2Can nature's beauty lift citizens from poverty? 2Can nature's beauty lift citizens from poverty? 3
Goat polyclonal to Ephrin B2 ( Abpromise for all tested applications). entrezGeneID: 1948 SwissProtID: P52799...
Pronase Reagent...
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
p38 MAP Kinase gamma Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: